+91 9425150513 (Asia) support@24lifesciences.com
Size, Share & Industry Analysis, By Type (Disposable Biopsy Forceps, Reusable Biopsy Forceps), By Application (Gastrointestinal Endoscopy, Laparoscopy, Bronchoscopy, Others), By End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics), By Jaw Configuration (Standard Cup Jaw, Alligator Jaw, Needle Forceps), By Material (Surgical Stainless Steel, Plastic/Polymer, Other Advanced Alloys), and Regional Forecast, 2026-2034
The global biopsy forceps market was valued at USD 672 million in 2025 and is estimated at USD 713 million in 2026. The market is projected to reach USD 1.145 billion by 2034, representing a 6.1% CAGR during 2026–2034.
Biopsy forceps are core tissue-acquisition tools used through endoscopes and related minimally invasive systems. Market demand is linked to procedure volume, diagnostic intensity, cancer and gastrointestinal workups, bronchoscopy, ENT examinations and the installed base of compatible scopes. Because the device directly contacts tissue, jaw geometry, cutting performance, sample adequacy and reliable opening and closing are central purchasing criteria.
Single-use devices dominate the report model, accounting for more than 85% of 2025 revenue. Infection-control requirements are a major structural reason: CDC guidance calls for reusable biopsy forceps and other cutting accessories that break the mucosal barrier to be mechanically cleaned and sterilized between each patient. Disposable products eliminate this reprocessing workflow and reduce cross-contamination concerns, although they create higher per-procedure consumable cost and waste.
The regulatory pipeline remains active across specialties. FDA cleared Olympus disposable biopsy forceps for bronchoscope use in May 2025, disposable hot biopsy forceps in October 2025, and disposable biopsy forceps used with nasopharyngoscopes in March 2026. These clearances show how manufacturers extend forceps platforms across endoscope types and procedural settings rather than competing only on a single general-purpose instrument.
Source: CDC disinfection and sterilization recommendations; FDA K250957; FDA K250187; FDA K252050.
The study covers biopsy forceps used to obtain tissue specimens through endoscopic, bronchoscopic, laparoscopic and related minimally invasive procedures, with analysis by reuse model, application, end user, jaw configuration, material and geography.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD million/billion |
| By Type | Disposable Biopsy Forceps; Reusable Biopsy Forceps |
| By Application | Gastrointestinal Endoscopy; Laparoscopy; Bronchoscopy; Others |
| By End User | Hospitals; Ambulatory Surgical Centers; Specialty Clinics |
| By Jaw Configuration | Standard Cup Jaw; Alligator Jaw; Needle Forceps |
| By Material | Surgical Stainless Steel; Plastic/Polymer; Other Advanced Alloys |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, India, South Korea, Australia, Brazil, Mexico, GCC countries and other major endoscopy markets |
| Key Market Players | Olympus Corporation; Boston Scientific Corporation; Cook Medical; KARL STORZ; HOYA Corporation (PENTAX Medical); Argon Medical Devices; CONMED Corporation; Cardinal Health; B. Braun; Micro-Tech; Bioags; Jiuhong; Anrui; Medtronic |
The market includes disposable and reusable biopsy forceps sold as stand-alone tissue-acquisition instruments or compatible accessories for report-defined minimally invasive procedures.
Biopsy needles, snares, cytology brushes, powered surgical graspers, endoscopes themselves, pathology services and imaging systems are outside core forceps revenue unless discussed as complementary or competing technologies.
Biopsy forceps are frequently replaced or consumed procedure by procedure, especially in single-use workflows. Growth in endoscopic evaluation and tissue diagnosis therefore translates directly into unit demand.
CDC recommends mechanical cleaning followed by sterilization of reusable biopsy forceps that break the mucosal barrier between each patient. Avoiding this complex workflow supports the commercial preference for single-use forceps.
Source: CDC.
Forceps must open, close, cut and retrieve tissue reliably through narrow endoscope channels. Clinicians and procurement teams evaluate jaw sharpness, cup volume, sheath flexibility, actuation consistency and specimen integrity.
Different scopes and specialties require specific lengths, diameters, working-channel compatibility and jaw designs. Manufacturers with broad endoscopy portfolios can cross-sell matched accessories and simplify customer qualification.
Disposable products reduce reprocessing burden but increase recurring consumable expense and medical waste. Reusable instruments retain a niche where validated sterilization systems and favorable procedure economics justify reprocessing.
Recent FDA clearances show forceps platforms being tailored for bronchoscopy, nasopharyngoscopy and hot biopsy use. This increases the number of procedure-specific SKUs and supports higher-value differentiation.
Hospitals can reduce cleaning validation, sterilization turnaround and accessory tracking by moving to disposable forceps. The economic comparison increasingly includes labor, reprocessing capacity and infection-control risk rather than purchase price alone.
Alligator, cup and needle-assisted configurations are selected for lesion type, tissue characteristics and access angle. Better specimen acquisition can reduce repeat sampling and support premium positioning.
As more endoscopic procedures move to ambulatory settings, facilities favor standardized, ready-to-use consumables that reduce central sterile processing dependency and inventory complexity.
A successful forceps design can be extended to additional compatible scopes and indications through regulatory submissions, allowing manufacturers to leverage core engineering across multiple specialties.
Standard non-electrosurgical forceps are used where mechanical sampling is sufficient and thermal injury is undesirable. Their value proposition centers on reliable tissue capture at low procedural complexity.
Electric biopsy forceps combine tissue sampling with coagulation functions in selected procedures and are regulated as Class II devices in the United States, increasing design and regulatory complexity.
Source: U.S. FDA.
Forceps must transmit opening force through long, flexible shafts while negotiating endoscope bends. Low-friction sheaths and robust pull-wire systems improve clinician control and reduce device failure.
Larger, cleaner specimens can improve histopathology yield and reduce the need for repeat procedures. Manufacturers therefore compete not only on device price but also on clinical workflow value.
The reuse model is the most commercially important segmentation because it changes infection-control workflow, unit economics and recurring revenue.
Disposable forceps accounted for more than 85% of report-defined 2025 revenue. Ready-to-use packaging, consistent cutting surfaces and elimination of cleaning and sterilization support their leading position.
Reusable forceps can lower instrument cost per case when facilities have validated reprocessing infrastructure and sufficient utilization. Their market is constrained by sterilization labor, tracking requirements and concerns about maintaining jaw performance over repeated cycles.
Application demand is linked to procedure volume and the need for definitive tissue diagnosis.
GI endoscopy is the largest application because forceps biopsy is routinely integrated into evaluation of mucosal abnormalities throughout the upper and lower gastrointestinal tract.
Laparoscopic forceps are used where surgeons require targeted tissue acquisition through minimally invasive ports. Products compete on reach, jaw strength and compatibility with surgical access systems.
Bronchoscopic biopsy requires long flexible instruments compatible with narrow working channels. FDA clearance activity in 2025 demonstrates active product development in this specialty.
Nasopharyngoscopy and other specialty endoscopic procedures create smaller but technically differentiated niches. FDA cleared an Olympus disposable forceps family for nasopharyngoscope use in March 2026.
End-user economics differ according to procedure volume, sterile-processing capability and purchasing scale.
Hospitals dominate because they perform broad endoscopy and surgical case mixes, maintain large scope fleets and purchase accessories through standardized contracts.
ASCs favor predictable case preparation and rapid turnover, making single-use forceps attractive where they reduce reprocessing dependencies.
Gastroenterology, pulmonology and ENT clinics purchase narrower portfolios matched to their procedures and compatible endoscopes.
Jaw geometry affects tissue bite, grip and specimen size.
Standard cups provide a familiar balance of tissue volume, maneuverability and broad compatibility, supporting their leading position across routine endoscopy.
Serrated or alligator-style jaws improve purchase on selected lesions or tissue surfaces and are used when secure grasping is a priority.
Needle-assisted configurations help anchor tissue before the cup closes, supporting sampling in locations where slippage can reduce specimen quality.
Material choice balances sharpness, corrosion resistance, manufacturability and cost.
Stainless steel remains the principal jaw material because it supports sharp cutting edges, corrosion resistance and established manufacturing processes.
Polymers are widely used in handles, sheaths and selected structural components, especially in disposable devices where molding efficiency and weight reduction matter.
Specialty alloys may be used where higher strength, fatigue resistance or specific mechanical properties justify added material cost.
North America led in 2025 through high endoscopy utilization, extensive hospital and ambulatory infrastructure, strong single-use adoption and rapid uptake of FDA-cleared device extensions.
Europe has a large installed endoscope base and stringent infection-control expectations. Competition is shaped by multinational suppliers, hospital procurement frameworks and sustainability scrutiny around disposable devices.
Asia-Pacific growth is supported by expanding hospital infrastructure, rising endoscopy capacity and regional manufacturing. China and Japan combine large procedure bases with established medical-device production.
Demand expands as private and public hospitals invest in endoscopy capacity. Price sensitivity creates a mixed market for premium multinational products and regional suppliers.
Growth is concentrated in tertiary hospitals and private specialty centers where modern endoscopy equipment and trained specialists are available.
Olympus, Boston Scientific, Cook Medical, PENTAX Medical and other large suppliers can bundle forceps with scopes, processors and other accessories, strengthening account relationships and compatibility assurance.
Regional manufacturers can win tenders with cost-effective disposable forceps and broad size configurations, particularly where buyers separate accessory procurement from capital endoscopy systems.
New forceps variants require documentation of performance, biocompatibility, sterilization and compatibility. Companies with established regulatory platforms can refresh portfolios faster across multiple specialties.
A disposable model creates repeat orders tied to procedure volume, making customer retention and supply continuity strategically important for manufacturers and distributors.
The following companies are covered in the competitive analysis and company-profile framework of the syndicated report.
FDA granted substantial-equivalence clearance to the FB-211D, FB-221D, FB-231D and FB-241D disposable biopsy forceps for use with bronchoscopes, expanding the forceps platform in pulmonary procedures.
Source: U.S. FDA.
FDA cleared FD-210U and FD-230U disposable hot biopsy forceps under the electric biopsy-forceps classification, supporting continued innovation in combined sampling and electrosurgical functionality.
Source: U.S. FDA.
FDA granted clearance to the FB-211D, FB-221D, FB-231D and FB-241D family for nasopharyngoscope use, extending the same platform into ENT procedures.
Source: U.S. FDA.
The biopsy forceps market is projected to expand from USD 713 million in 2026 to USD 1.145 billion by 2034. Growth will be driven by recurring endoscopy procedure demand, continued single-use adoption and specialty-specific portfolio expansion.
| Forecast Theme | 2026–2034 Market Implication |
|---|---|
| Disposable forceps | Single-use products will retain the largest revenue pool because they simplify infection-control workflow and create recurring consumable demand. |
| GI endoscopy | High procedure volumes will keep gastrointestinal applications as the largest demand base. |
| Specialty extensions | Bronchoscopy and ENT-specific clearances will create incremental high-value niches. |
| Ambulatory care | Migration of procedures to ASCs will favor standardized ready-to-use accessory packs. |
| Sustainability and cost | Manufacturers will face pressure to reduce packaging, waste and total procedure cost while maintaining sterility and performance. |
2025 base, 2026 estimate and 2034 forecast for biopsy-forceps revenue.
Disposable versus reusable forceps and the economics of reprocessing.
GI endoscopy, laparoscopy, bronchoscopy, hospitals, ASCs and specialty clinics.
Cup, alligator and needle configurations plus stainless steel and polymer components.
Regional leadership and selective regulatory country signals.
FDA clearance activity and CDC reprocessing requirements affecting product choice.
The biopsy forceps market study combines top-down market reconciliation with bottom-up analysis of product categories, end-use demand, company participation and country-level commercial conditions. Secondary research draws on regulators, public-health agencies, professional bodies, peer-reviewed literature, official statistics and primary company disclosures, while primary research is used to test market boundaries, channel structure, pricing behavior and adoption assumptions.
Historical and current evidence is reconciled against the report segmentation so that the 2025 base year, 2026 estimate and 2034 forecast use consistent definitions. Forecast assumptions consider underlying demand indicators, clinical or operational adoption, regulatory change, competitive intensity, procurement behavior, pricing pressure and regional access conditions rather than extending a single historical trend mechanically.
Company disclosures and public utilization indicators are used as market-development evidence and are not substituted for the report’s defined market-revenue boundaries.
The market was valued at USD 672 million in 2025, is estimated at USD 713 million in 2026 and is projected to reach USD 1.145 billion by 2034, representing a 6.1% CAGR during 2026–2034.
Disposable biopsy forceps lead and represented more than 85% of report-defined 2025 revenue.
Gastrointestinal endoscopy is the leading application because tissue sampling is routinely integrated into diagnostic endoscopic procedures.
North America was the largest regional market in 2025, supported by high endoscopy volumes, advanced care infrastructure and strong disposable-device adoption.
They arrive ready for use and eliminate the cleaning and sterilization workflow required for reusable biopsy forceps that break the mucosal barrier.
Regulation depends on device type and intended use. Electric biopsy forceps are Class II devices, and recent disposable forceps variants have received 510(k) clearances for specific endoscope applications.
The report profiles global endoscopy leaders and specialist medical-device manufacturers active in biopsy forceps.
The forecast period is 2026–2034, with 2025 as the base year and 2026 as the estimated year.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.
